<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04971590</url>
  </required_header>
  <id_info>
    <org_study_id>216989</org_study_id>
    <nct_id>NCT04971590</nct_id>
  </id_info>
  <brief_title>Study to Assess Demographic, Pharmacologic, Biomarker, Clinical Features and Quality of Life (QoL) of Participants With Lupus Nephritis</brief_title>
  <official_title>LUNELORD: A Descriptive, Prospective Study to Assess Demographic, Pharmacologic, Biomarker, Clinical Features and QoL of Patients With LUpus NEphritis and Long-term ORgan Damage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter prospective study to assess clinical characteristics, demographics,&#xD;
      treatment and health-related quality of life (HRQoL) of lupus nephritis (LN) participants&#xD;
      across 5 Gulf countries (United Arab Emirates [UAE], Qatar, Bahrain, Kuwait and Oman).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 19, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with demographic characteristics</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with clinical manifestations of Lupus Nephritis</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with comorbidities</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Severity of Lupus Nephritis in participants</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with treatments for lupus nephritis</measure>
    <time_frame>Up to 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>36-Item Short Form Health Survey (SF-36) total score</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The SF-36 is a 36-item QoL questionnaire covering 8 health domains. Scores for each domain range from 0 to 100, with a higher score defining a more favorable health state.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with refractory Lupus Nephritis</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in anti-nuclear antibody</measure>
    <time_frame>Baseline and up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in antibody to double-stranded deoxyribonucleic acid test (anti-dsDNA antibody)</measure>
    <time_frame>Baseline and up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in complement (C3 and C4) levels</measure>
    <time_frame>Baseline and up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with renal remission</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in the SF-36 physical and mental components score and the total scores at one year (Scores on a scale)</measure>
    <time_frame>Baseline and 1 year</time_frame>
    <description>The SF-36 is a 36-item QoL questionnaire covering 8 health domains. Scores for each domain range from 0 to 100, with a higher score defining a more favorable health state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with healthcare resource utilization (HCRU)</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direct medical costs associated with lupus nephritis management</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with difference in treatment patterns</measure>
    <time_frame>Up to 1 year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Participants with Lupus Nephritis</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Participant completed survey</intervention_name>
    <description>Participants will be required to complete the participant survey.</description>
    <arm_group_label>Participants with Lupus Nephritis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Medical chart review</intervention_name>
    <description>Data will be collected from medical charts of participants.</description>
    <arm_group_label>Participants with Lupus Nephritis</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with lupus nephritis as defined by physician per participants hospital records&#xD;
        prior to the enrolment visit or at diagnosis.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  More than or equal to 18 years of age&#xD;
&#xD;
          -  Clinician diagnosed LN participants.&#xD;
&#xD;
          -  At least one visit to the investigational center during 12 months prior to the&#xD;
             baseline visit, recorded in medical documentation.&#xD;
&#xD;
          -  Literacy in English or Arabic allowing to fully comprehend the written informed&#xD;
             consent and study-specific patient reported questionnaires.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Incomplete medical records to be able to assess the disease severity or absence of any&#xD;
             of the following renal laboratory results from the medical record within the last&#xD;
             twelve months: a. Urinary protein to creatinine ratio (UPCR) or 24-hour proteinuria or&#xD;
             urine sediment (activity). b. Serum creatinine or estimated glomerular filtration rate&#xD;
             (eGFR); or measured glomerular filtration rate (GFR), if eGFR is not available.&#xD;
&#xD;
          -  Current or medical history of: a. Congenital or acquired immunodeficiency. b.&#xD;
             Malignancy in active treatment phase. c. Acute viral infection, such as human&#xD;
             immunodeficiency virus (HIV) infection, requiring hospitalization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 12, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LUNELORD</keyword>
  <keyword>Systemic lupus erythematosus</keyword>
  <keyword>Lupus nephritis</keyword>
  <keyword>Organ damage</keyword>
  <keyword>Gulf countries</keyword>
  <keyword>Real-world</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

